Reneo Pharmaceuticals, Inc. (RPHM)
- Previous Close
1.3100 - Open
1.3101 - Bid 1.0100 x 200
- Ask 1.6800 x 200
- Day's Range
1.3101 - 1.4000 - 52 Week Range
0.9800 - 9.2100 - Volume
145,933 - Avg. Volume
130,140 - Market Cap (intraday)
44.627M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6800 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.25
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
reneopharma.comRecent News: RPHM
View MorePerformance Overview: RPHM
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPHM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPHM
View MoreValuation Measures
Market Cap
43.79M
Enterprise Value
-32.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.72%
Return on Equity (ttm)
-54.00%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-56.54M
Diluted EPS (ttm)
-1.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
76.67M
Total Debt/Equity (mrq)
1.07%
Levered Free Cash Flow (ttm)
-43.42M